urea has been researched along with Diabetes Mellitus, Adult-Onset in 112 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the anti proteinuric effect of pentoxifylline in diabetic patients, we prospectively studied in 25 hypertensive type 2 diabetic patients with persistent microalbuminuria and normal renal function the impact of combining pentoxifylline with an angiotensin converting enzyme inhibitor, lisinopril, on urinary albumin excretion and compared the results with those obtained in a control group of 25 type 2 diabetic patients treated with lisinopril only." | 9.10 | Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003) |
| "Dysregulation of the urea cycle (UC) has been detected in colorectal cancer (CRC)." | 8.84 | Association between serum urea concentrations and the risk of colorectal cancer, particularly in individuals with type 2 diabetes: A cohort study. ( Chen, X; Gao, P; Jiang, Y; Liu, Z; Mei, Z; Suo, C; Xu, K; Yuan, H; Zhang, T; Zhao, R; Zhu, D, 2024) |
| "Measurement of urinary electrolytes and urea revealed that an osmotic diuresis induced by urea derived principally by breakdown of endogenous protein was causative." | 7.79 | Severe hypernatremia from a urea-induced diuresis due to body protein wasting in an insulin-resistant type 2 diabetic patient. ( Anderson, A; Barrett, EJ, 2013) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 7.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| "Mifepristone was administered at doses of 300-1200 mg daily." | 6.77 | Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. ( Biller, BM; Findling, JW; Fleseriu, M; Gross, C; Molitch, ME; Schteingart, DE, 2012) |
| "Depression and type 2 diabetes (T2D) are serious public health problems with irreversible health consequences and a significant economic burden on the healthcare system." | 5.72 | Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study. ( Geng, Y; Li, X; Ma, J; Mao, Y; Zhao, Y; Zhu, S, 2022) |
| "Type 2 diabetes is associated with excessively low urine pH, which increases the risk for uric acid nephrolithiasis." | 5.14 | Metabolic basis for low urine pH in type 2 diabetes. ( Cameron, MA; Maalouf, NM; Moe, OW; Sakhaee, K, 2010) |
| "To investigate the anti proteinuric effect of pentoxifylline in diabetic patients, we prospectively studied in 25 hypertensive type 2 diabetic patients with persistent microalbuminuria and normal renal function the impact of combining pentoxifylline with an angiotensin converting enzyme inhibitor, lisinopril, on urinary albumin excretion and compared the results with those obtained in a control group of 25 type 2 diabetic patients treated with lisinopril only." | 5.10 | Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. ( Harmankaya, O; Seber, S; Yilmaz, M, 2003) |
| "04), urinary urea nitrogen and proteinuria (P<0." | 5.10 | Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy. ( Atabak, S; Azadbakht, L; Esmaill-Zadeh, A; Jamshidian, M; Mehrabi, Y; Shakerhosseini, R, 2003) |
| " This review provides an overview of 5-HT receptor pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, which target the 5HT2C and 5HT2A receptors and provide new treatments for obesity and Parkinson's disease psychosis, respectively." | 4.89 | Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. ( Meltzer, HY; Roth, BL, 2013) |
| "Dysregulation of the urea cycle (UC) has been detected in colorectal cancer (CRC)." | 4.84 | Association between serum urea concentrations and the risk of colorectal cancer, particularly in individuals with type 2 diabetes: A cohort study. ( Chen, X; Gao, P; Jiang, Y; Liu, Z; Mei, Z; Suo, C; Xu, K; Yuan, H; Zhang, T; Zhao, R; Zhu, D, 2024) |
| " There were significant negative correlations between the macular thickness values of parafoveal areas and serum urea, HbA1c, albumin, microalbuminuria levels (p < 0." | 3.96 | Effect of microalbuminuria on macular thickness in patients with type-2 diabetes mellitus. ( Atilgan, KG; Caglayan, M; Kosekahya, P; Sendul, SY; Ucgul Atilgan, C; Yilmazbas, P, 2020) |
| "To evaluate the role of serum urea and creatinine as surrogate markers for disruption of retinal photoreceptor external limiting membrane (ELM) and inner segment ellipsoid zone (EZ) in Type 2 diabetic retinopathy (DR) using spectral-domain optical coherence tomography, for the first time." | 3.85 | INCREASED SERUM LEVELS OF UREA AND CREATININE ARE SURROGATE MARKERS FOR DISRUPTION OF RETINAL PHOTORECEPTOR EXTERNAL LIMITING MEMBRANE AND INNER SEGMENT ELLIPSOID ZONE IN TYPE 2 DIABETES MELLITUS. ( Akduman, L; Gilhotra, JS; Jain, A; Kruzliak, P; Meyer, CH; Mishra, N; Natu, SM; Prasad, S; Ruia, S; Saxena, S, 2017) |
| " Moreover positive correlation was found between sialic acid ganglioside and blood glucose, HbA1c, urea, creatinine, microalbuminuria in patients with diabetic nephropathy." | 3.83 | Monitoring Diabetic Nephropathy by Circulating Gangliosides. ( Anghel, A; Budu, V; Ene, CD; Neagu, M; Nicolae, I; Penescu, M, 2016) |
| "Measurement of urinary electrolytes and urea revealed that an osmotic diuresis induced by urea derived principally by breakdown of endogenous protein was causative." | 3.79 | Severe hypernatremia from a urea-induced diuresis due to body protein wasting in an insulin-resistant type 2 diabetic patient. ( Anderson, A; Barrett, EJ, 2013) |
| " Glycerol in T2DM microdialysate (but not in T1DM) was higher than in healthy volunteers, which is likely explained by sc insulin resistance (insulin is a potent antilipolytic hormone)." | 3.76 | Analyte flux at a biomaterial-tissue interface over time: implications for sensors for type 1 and 2 diabetes mellitus. ( Adamson, U; Brismar, K; Ekberg, NR; Hedblad, MA; Malmstedt, J; Ungerstedt, U; Wisniewski, N, 2010) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 3.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| " Between 6 and 12 months of age, eSS male rats had higher fructosamine values and glucose intolerance as well as increasing proteinuria and uremia." | 3.70 | Onset and evolution of nephropathy in rats with spontaneous diabetes mellitus. ( Arriaga, S; D'Ottavio, AE; Daniele, SM; Hisano, N; Martínez, SM; Montenegro, SM; Morisoli, L; Picena, JC; Tarrés, MC, 2000) |
| "Mifepristone was administered at doses of 300-1200 mg daily." | 2.77 | Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. ( Biller, BM; Findling, JW; Fleseriu, M; Gross, C; Molitch, ME; Schteingart, DE, 2012) |
| "Eight men with type 2 diabetes mellitus ingested a control diet (15% protein, 55% carbohydrate, and 30% fat) and a LoBAG(30) diet for 5 weeks in a randomized crossover design with a washout period in between." | 2.76 | Effect of a high-protein diet on ghrelin, growth hormone, and insulin-like growth factor-I and binding proteins 1 and 3 in subjects with type 2 diabetes mellitus. ( Gannon, MC; Nuttall, FQ, 2011) |
| "No effect was observed on renal hemodynamic parameters." | 2.72 | Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. ( Bohnemeier, H; Chadha-Boreham, H; Dingemanse, J; Halabi, A; Jungnik, A; Krähenbühl, S; Sidharta, PN; Wagner, FD, 2006) |
| "Thirty hypertensive diabetic nephropathy patients with moderate hypertension were studied." | 2.70 | Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy. ( Arije, A; Finomo, FO; Kadiri, S; Olatosin, AO; Salako, BL, 2002) |
| "In 10 patients with type 2 diabetes in poor metabolic control, urea synthesis and amino acid to urea nitrogen exchange were measured in the basal state and during an alanine load (6 hours) with 2-hour superinfusion of a PGE1 analog (30 microg/h) or saline in random order." | 2.70 | Systemic prostaglandin E1 infusion and hepatic aminonitrogen to urea nitrogen conversion in patients with type 2 diabetes in poor metabolic control. ( Baraldi, L; Bianchi, G; Brizi, M; Forlani, G; Marchesini, G; Melchionda, N; Natale, S; Zaccheroni, V, 2001) |
| "4." | 2.69 | Levels of lactic acid, normal level & its relation to food, glucose, cholesterol, raised blood urea and phenformin therapy. ( Amin, BM; Patel, JC; Sawant, MS, 2000) |
| "The diagnosis of Type 2 Diabetes Mellitus (T2DM) is made by demonstrating the hypoglycemic condition, which involves the determination of plasma glucose, and the follow-up of hypoglycemic treatment is performed by assessing the glycated hemoglobin (HbA1c) concentration." | 1.91 | Use of Saliva to Assess the Adherence to Treatment with Oral Hypoglycemic Agents in Patients with Type 2 Diabetes. ( Castelo, PM; da Costa Aguiar Alves, B; da Veiga, GL; de Faria Baltazar, H; Fonseca, FLA; Gascón, T; Pereira, EC, 2023) |
| "28 subjects with type 2 diabetes (T2D) were enrolled." | 1.91 | Effects of Dietary Sodium and Protein Intake on Glomerular Filtration Rate in Subjects with Type 2 Diabetes Treated with Sodium-Glucose Cotransporter 2 Inhibitors. ( Baggiore, CM; Colombi, C; Gaudio, C; Merciai, C; Rosati, A; Seghieri, M; Spatoliatore, G, 2023) |
| "A total of 405 type 2 diabetes patients were enrolled in this study." | 1.72 | The association between time in the glucose target range and abnormal ankle-brachial index: a cross-sectional analysis. ( Feng, Z; Gu, P; Lei, H; Liu, C; Liu, J; Liu, Y; Lu, B; Shao, J; Shen, Q; Wei, Y; Yang, X; Zhang, Z; Zhou, H, 2022) |
| "Depression and type 2 diabetes (T2D) are serious public health problems with irreversible health consequences and a significant economic burden on the healthcare system." | 1.72 | Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study. ( Geng, Y; Li, X; Ma, J; Mao, Y; Zhao, Y; Zhu, S, 2022) |
| "Maturity-onset Diabetes of Young (MODY) is a monogenic form of diabetes affecting 1-5% of young (often ≤25 years) diabetic patients exhibiting an autosomal dominant mode of inheritance." | 1.72 | Clinical profiling and screening for HNF4α and GCK gene mutations in Kashmiri patients with maturity-onset diabetes of the young (MODY). ( Firdous, P; Ganai, BA; Hassan, T; Masoodi, SR; Nissar, K, 2022) |
| "To evaluate salivary factors in type 2 diabetes melliuts patients." | 1.51 | Salivary Profile in Adult Type 2 Diabetes Mellitus Patients: A Case-control Study. ( Mozaffari, HR; Naseri, R; Nikray, S; Raygani, AV; Sadeghi, M; Sharifi, R, 2019) |
| "Pioglitazone was generally more effective than vildagliptin in the studied parameters except for the lipid profile where the effect of both drugs was comparable and for the liver enzymes and renal parameters where vildagliptin was more effective." | 1.43 | Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. ( El Sarha, A; Refaat, R; Sakr, A; Salama, M, 2016) |
| "Hyperglycemia in type 2 diabetes mellitus has been linked to non-alcoholic fatty liver disease, which can progress to inflammation, fibrosis/cirrhosis, and hepatocellular carcinoma." | 1.43 | Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. ( Ballinger, KR; Davidson, MD; Khetani, SR, 2016) |
| "A total of 100 (50 with type 2 diabetes and 50 controls) participants were recruited for our study." | 1.43 | A case-control study of prevalence of anemia among patients with type 2 diabetes. ( Adjei, JK; Antwi-Bafour, S; Ekem, I; Hammond, S; Kyeremeh, R; Martin-Odoom, A, 2016) |
| "6) % was achieved on prescribed metformin dosage of 2550 (2000-2550) mg per day." | 1.40 | The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment. ( Dolžan, V; Goričar, K; Janež, A; Klen, J, 2014) |
| "In time, HIP rats developed cardiac hypertrophy and left-ventricular dilation." | 1.40 | Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model. ( Chiamvimonvat, N; Despa, F; Despa, S; Dong, H; Hammock, BD; Harris, TR; Li, N; Margulies, KB; Sharma, S; Taegtmeyer, H, 2014) |
| "Of the 2630 type 2 diabetes subjects newly registered in 1996, 152 (M:F;92:60) normoalbuminuric subjects had baseline and subsequent measurements of anthropometric, haemodynamic and biochemical details spanning 12 years." | 1.38 | Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: a 12 years observational study. ( Kumpatla, S; Tilak, P; Viswanathan, V, 2012) |
| "University of California-Davis-type 2 diabetes mellitus (UCD-T2DM) rats with nonfasting blood glucose levels in the range of 150-200 mg/dl were treated with the sEH inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) for 6 wk." | 1.38 | Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. ( Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V, 2012) |
| "A rat model of type 2 diabetes was established by intraperitoneal injection of small doses of streptozotocin combined with high calorie feeding." | 1.35 | Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro. ( Hong, G; Wu, GZ; Zhang, HB; Zhang, WP, 2009) |
| "The early stages of renal failure are poorly diagnosed by current routine tests." | 1.35 | Early renal failure detection by cystatin C in Type 2 diabetes mellitus: varying patterns of renal analyte expression. ( Bwititi, P; Car, G; Chen, R; Janu, MR; McNamara, NV; Seibel, M, 2009) |
| "Myo-inositol was even more elevated in patients with polyneuropathy (p = 0." | 1.32 | Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy. ( Feuerbach, S; Fründ, R; Geissler, A; Schölmerich, J; Zietz, B, 2003) |
| "Urinary VEGF excretions increased as diabetic nephropathy advanced." | 1.32 | Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. ( Baik, SH; Cha, DR; Choi, DS; Choi, KM; Han, KH; Han, SY; Ji, YH; Kang, YS; Kim, DL; Kim, KB; Kim, NH; Kim, SG, 2004) |
| "Leptin is a protein hormone produced predominantly by adipocytes that affects food intake and energy expenditure." | 1.31 | Serum leptin levels in diabetic patients on hemodialysis: the relationship to parameters of diabetes metabolic control. ( Bedárová, V; Bodláková, B; Haas, T; Haluzik, M; Jiskra, J; Marková, M; Sulková, S; Svobodová, J; Turková, G, 2000) |
| " In this study, the anti-obesity effects of SB-334867-A were determined in genetically obese (ob/ob) mice dosed with SB-334867-A (30 mg/kg, i." | 1.31 | Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. ( Arch, JR; Cawthorne, MA; Chapman, H; Clapham, JC; Haynes, AC; Moore, GB; Tadayyon, M; Taylor, C, 2002) |
| "This locus, which we named Mody4, was mapped to chromosome 7 in a region 2-8 cM distal to D7Mit189 (logarithm of odds [LOD] score = 15." | 1.30 | A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. ( Ikeda, T; Kayo, T; Koizumi, A; Yoshioka, M, 1997) |
| "We conclude that PIDDM patients have more severe renal dysfunction than NIDDM patients and, since glycosylated haemoglobin concentrations are comparable in these groups, we attribute this to a renal insult due to malnutrition predating the onset of the PIDDM." | 1.30 | Kidney function in phasic insulin dependent diabetes mellitus in Jamaica. ( Bennett, F; Morrison, EY; Ragoobirsingh, D, 1997) |
| "4." | 1.29 | Levels of lactic acid in normal Indians & its relation to food, glucose, cholesterol, raised blood urea. ( Patel, JC; Sawant, MS, 1993) |
| "Seventy-one consecutive NIDDM patients attending an outpatient clinic, with Albustix-tested negative urine and a 24-h AER < 200 micrograms/min, were examined for long-term complications of diabetes." | 1.29 | Glomerular hyperfiltration in NIDDM patients without overt proteinuria. ( Friedman, R; Gross, JL; Silveiro, SP, 1993) |
| "The PET data from 11 IDDM patients (2 female, 9 male) and 13 NIDDM patients (3 female, 10 male) were reviewed." | 1.29 | Peritoneal transport in type I (insulin-dependent) and type II (noninsulin-dependent) diabetic peritoneal dialysis patients. ( Cabralda, T; Lin, JJ; Suh, H; Wadhwa, NK, 1995) |
| "The body weight has a bearing on the level of risk factors, i." | 1.28 | [The effect of elevated blood glucose levels and body weight on the metabolic profile in type 2 diabetes after long-term therapy]. ( Grafnetter, D; Jirkovská, A; Karasová, I; Pelikánová, J; Válek, J; Vlasáková, Z, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.79) | 18.7374 |
| 1990's | 14 (12.50) | 18.2507 |
| 2000's | 28 (25.00) | 29.6817 |
| 2010's | 44 (39.29) | 24.3611 |
| 2020's | 24 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Abdou, AE | 1 |
| Anani, HAA | 1 |
| Ibrahim, HF | 1 |
| Ebrahem, EE | 1 |
| Seliem, N | 1 |
| Youssef, EMI | 1 |
| Ghoraba, NM | 1 |
| Hassan, AS | 1 |
| Ramadan, MAA | 1 |
| Mahmoud, E | 1 |
| Issa, S | 1 |
| Maghraby, HM | 1 |
| Abdelrahman, EK | 1 |
| Hassan, HAM | 1 |
| Akiu, M | 1 |
| Tsuji, T | 1 |
| Iida, K | 1 |
| Sogawa, Y | 1 |
| Terayama, K | 1 |
| Yokoyama, M | 1 |
| Tanaka, J | 1 |
| Asano, D | 1 |
| Honda, T | 1 |
| Sakurai, K | 1 |
| Pinkerton, AB | 1 |
| Nakamura, T | 1 |
| Firdous, P | 1 |
| Hassan, T | 1 |
| Nissar, K | 1 |
| Masoodi, SR | 1 |
| Ganai, BA | 1 |
| Fuglsang-Nielsen, R | 1 |
| Rakvaag, E | 1 |
| Vestergaard, P | 1 |
| Hermansen, K | 1 |
| Gregersen, S | 1 |
| Starup-Linde, J | 1 |
| Lerman, JB | 1 |
| Giamberardino, SN | 1 |
| Hernandez, AF | 1 |
| Felker, GM | 1 |
| Shah, SH | 1 |
| McGarrah, RW | 1 |
| Khan, A | 1 |
| Jahan, I | 1 |
| Nayeem, SM | 1 |
| Ma, CM | 1 |
| Wang, N | 1 |
| Su, QW | 1 |
| Yan, Y | 1 |
| Wang, SQ | 1 |
| Ma, CH | 1 |
| Liu, XL | 1 |
| Dong, SC | 1 |
| Lu, N | 1 |
| Yin, LY | 1 |
| Yin, FZ | 1 |
| Wang, YW | 1 |
| Tan, H | 2 |
| Wang, X | 6 |
| Ye, K | 1 |
| Lin, J | 2 |
| Song, E | 1 |
| Gong, L | 1 |
| Antonijević, A | 1 |
| Stojanović, E | 1 |
| Jevtić, A | 1 |
| Živković, V | 1 |
| Bolevich, S | 1 |
| Jakovljević, V | 1 |
| Liu, G | 1 |
| Lin, Y | 1 |
| Wei, C | 1 |
| Liu, S | 1 |
| Xu, Y | 2 |
| Mao, Y | 3 |
| Li, X | 14 |
| Zhu, S | 3 |
| Ma, J | 3 |
| Geng, Y | 3 |
| Zhao, Y | 5 |
| Wei, Y | 4 |
| Liu, C | 5 |
| Liu, Y | 6 |
| Zhang, Z | 2 |
| Feng, Z | 2 |
| Yang, X | 5 |
| Liu, J | 2 |
| Lei, H | 2 |
| Zhou, H | 2 |
| Shen, Q | 2 |
| Lu, B | 2 |
| Gu, P | 2 |
| Shao, J | 2 |
| de Faria Baltazar, H | 1 |
| Fonseca, FLA | 1 |
| Castelo, PM | 1 |
| da Costa Aguiar Alves, B | 1 |
| Gascón, T | 1 |
| da Veiga, GL | 1 |
| Pereira, EC | 1 |
| Bioletto, F | 1 |
| Varaldo, E | 1 |
| Prencipe, N | 1 |
| Benso, A | 1 |
| Berton, AM | 1 |
| Gaudio, C | 1 |
| Seghieri, M | 1 |
| Merciai, C | 1 |
| Colombi, C | 1 |
| Spatoliatore, G | 1 |
| Baggiore, CM | 1 |
| Rosati, A | 1 |
| Zhang, W | 1 |
| Zheng, J | 2 |
| Zhang, J | 4 |
| Li, N | 2 |
| Fang, ZZ | 1 |
| Zhang, Q | 3 |
| Gao, P | 1 |
| Mei, Z | 2 |
| Liu, Z | 3 |
| Zhu, D | 1 |
| Yuan, H | 1 |
| Zhao, R | 1 |
| Xu, K | 1 |
| Zhang, T | 3 |
| Jiang, Y | 2 |
| Suo, C | 1 |
| Chen, X | 2 |
| Moore, KBE | 1 |
| Horgan, NG | 1 |
| Lenters, B | 1 |
| Fortin, JS | 2 |
| Tan, JKS | 1 |
| Wei, X | 1 |
| Wong, PA | 1 |
| Fang, J | 2 |
| Kim, S | 1 |
| Agrawal, R | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 2 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, Y | 3 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Wang, J | 5 |
| Zhang, E | 1 |
| Li, Y | 7 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Wang, Y | 4 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Li, J | 7 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, W | 1 |
| Wang, S | 3 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 2 |
| Zhu, J | 2 |
| Zhang, L | 3 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 4 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Zhang, Y | 4 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Gao, Y | 3 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 1 |
| Zhang, M | 4 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Yao, Y | 1 |
| Liang, C | 1 |
| Yang, H | 2 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Wang, Q | 3 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 5 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 2 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 2 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 2 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 2 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 2 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 1 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 2 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Elizalde-Velázquez, GA | 1 |
| Gómez-Oliván, LM | 1 |
| Islas-Flores, H | 1 |
| Hernández-Navarro, MD | 1 |
| García-Medina, S | 1 |
| Galar-Martínez, M | 1 |
| S, S | 1 |
| R, K | 1 |
| P, S | 1 |
| Li, R | 1 |
| Jing, Q | 1 |
| Yang, M | 1 |
| Han, X | 2 |
| Yu, X | 1 |
| Lokesh, V | 1 |
| Lakshmikantha, A | 1 |
| Kannan, S | 1 |
| Pojskić, L | 1 |
| Hasić, S | 1 |
| Tahto, E | 1 |
| Arnautović-Torlak, V | 1 |
| Pojskić, B | 1 |
| Zayed, AE | 1 |
| Saleh, A | 1 |
| Gomaa, AMS | 1 |
| Abd-Elkareem, M | 1 |
| Anwar, MM | 1 |
| Hassanein, KMA | 1 |
| Elsherbiny, MM | 1 |
| Kotb, AM | 1 |
| Ucgul Atilgan, C | 1 |
| Atilgan, KG | 1 |
| Kosekahya, P | 1 |
| Caglayan, M | 1 |
| Sendul, SY | 1 |
| Yilmazbas, P | 1 |
| Di Leva, FS | 1 |
| Festa, C | 1 |
| Carino, A | 1 |
| De Marino, S | 1 |
| Marchianò, S | 1 |
| Di Marino, D | 1 |
| Finamore, C | 1 |
| Monti, MC | 1 |
| Zampella, A | 1 |
| Fiorucci, S | 1 |
| Limongelli, V | 1 |
| Mozaffari, HR | 1 |
| Sharifi, R | 1 |
| Raygani, AV | 1 |
| Sadeghi, M | 1 |
| Nikray, S | 1 |
| Naseri, R | 1 |
| Savina, Y | 1 |
| Duflot, T | 1 |
| Bounoure, F | 1 |
| Kotzki, S | 1 |
| Thiebaut, PA | 1 |
| Serreau, PA | 1 |
| Skiba, M | 1 |
| Picquenot, JM | 1 |
| Cornic, M | 1 |
| Morisseau, C | 1 |
| Hammock, B | 1 |
| Imbert, L | 1 |
| Cracowski, JL | 1 |
| Richard, V | 1 |
| Roustit, M | 1 |
| Bellien, J | 1 |
| Anderson, A | 1 |
| Barrett, EJ | 1 |
| Seeliger, J | 1 |
| Estel, K | 1 |
| Erwin, N | 1 |
| Winter, R | 1 |
| Abrahão, SA | 1 |
| Pereira, RG | 1 |
| de Sousa, RV | 1 |
| Lima, AR | 1 |
| Crema, GP | 1 |
| Barros, BS | 1 |
| Ramírez-Zamora, S | 1 |
| Méndez-Rodríguez, ML | 1 |
| Olguín-Martínez, M | 1 |
| Sánchez-Sevilla, L | 1 |
| Quintana-Quintana, M | 1 |
| García-García, N | 1 |
| Hernández-Muñoz, R | 1 |
| Koskela, HO | 1 |
| Salonen, PH | 1 |
| Niskanen, L | 1 |
| Meltzer, HY | 1 |
| Roth, BL | 1 |
| Klen, J | 1 |
| Goričar, K | 1 |
| Janež, A | 1 |
| Dolžan, V | 1 |
| Otlivanchik, O | 1 |
| Le Foll, C | 1 |
| Levin, BE | 1 |
| Despa, S | 2 |
| Sharma, S | 1 |
| Harris, TR | 2 |
| Dong, H | 2 |
| Chiamvimonvat, N | 2 |
| Taegtmeyer, H | 1 |
| Margulies, KB | 1 |
| Hammock, BD | 2 |
| Despa, F | 2 |
| Federici, A | 2 |
| Federici, G | 2 |
| Milani, M | 2 |
| Bukhari, SA | 1 |
| Javed, S | 1 |
| Ali, M | 1 |
| Shahzadi, A | 1 |
| Rehman, M | 1 |
| Kantsadi, AL | 1 |
| Parmenopoulou, V | 1 |
| Bakalov, DN | 1 |
| Snelgrove, L | 1 |
| Stravodimos, GA | 1 |
| Chatzileontiadou, DS | 1 |
| Manta, S | 1 |
| Panagiotopoulou, A | 1 |
| Hayes, JM | 1 |
| Komiotis, D | 1 |
| Leonidas, DD | 1 |
| Liu, B | 1 |
| Hu, H | 1 |
| Yuan, J | 1 |
| Yao, P | 1 |
| Wei, S | 1 |
| Liang, Y | 1 |
| Miao, X | 1 |
| Guo, H | 1 |
| He, M | 1 |
| Ene, CD | 1 |
| Penescu, M | 1 |
| Anghel, A | 1 |
| Neagu, M | 1 |
| Budu, V | 1 |
| Nicolae, I | 1 |
| Benoit-Biancamano, MO | 1 |
| C-Gaudreault, R | 1 |
| Lima-Aragão, MV | 1 |
| de Oliveira-Junior, Jde J | 1 |
| Maciel, MC | 1 |
| Silva, LA | 1 |
| do Nascimento, FR | 1 |
| Guerra, RN | 1 |
| Antwi-Bafour, S | 1 |
| Hammond, S | 1 |
| Adjei, JK | 1 |
| Kyeremeh, R | 1 |
| Martin-Odoom, A | 1 |
| Ekem, I | 1 |
| Davidson, MD | 1 |
| Ballinger, KR | 1 |
| Khetani, SR | 1 |
| Comar, JF | 1 |
| de Oliveira, DS | 1 |
| Bracht, L | 1 |
| Kemmelmeier, FS | 1 |
| Peralta, RM | 1 |
| Bracht, A | 1 |
| Ong, CN | 1 |
| Subramaniam, T | 1 |
| Choi, HW | 1 |
| Yuan, JM | 1 |
| Koh, WP | 1 |
| Pan, A | 1 |
| Refaat, R | 1 |
| Sakr, A | 1 |
| Salama, M | 1 |
| El Sarha, A | 1 |
| Allison, SJ | 1 |
| Saxena, S | 1 |
| Ruia, S | 1 |
| Prasad, S | 1 |
| Jain, A | 1 |
| Mishra, N | 1 |
| Natu, SM | 1 |
| Meyer, CH | 1 |
| Gilhotra, JS | 1 |
| Kruzliak, P | 1 |
| Akduman, L | 1 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, T | 1 |
| Inoshita, A | 1 |
| Ikeda, K | 1 |
| Uto, E | 1 |
| Kikuchi, F | 1 |
| Matsumoto, K | 1 |
| Thomson, SA | 1 |
| Banker, P | 1 |
| Bickett, DM | 1 |
| Boucheron, JA | 1 |
| Carter, HL | 1 |
| Clancy, DC | 1 |
| Cooper, JP | 1 |
| Dickerson, SH | 1 |
| Garrido, DM | 1 |
| Nolte, RT | 1 |
| Peat, AJ | 1 |
| Sheckler, LR | 1 |
| Sparks, SM | 1 |
| Tavares, FX | 1 |
| Wang, TY | 1 |
| Weiel, JE | 1 |
| McNamara, NV | 1 |
| Chen, R | 1 |
| Janu, MR | 1 |
| Bwititi, P | 1 |
| Car, G | 1 |
| Seibel, M | 1 |
| Azadbakht, L | 2 |
| Esmaillzadeh, A | 1 |
| Sidharta, PN | 2 |
| Rave, K | 1 |
| Heinemann, L | 1 |
| Chiossi, E | 1 |
| Krähenbühl, S | 2 |
| Dingemanse, J | 3 |
| Wu, GZ | 1 |
| Hong, G | 1 |
| Zhang, WP | 1 |
| Zhang, HB | 1 |
| Sobngwi, E | 1 |
| Enoru, S | 1 |
| Ashuntantang, G | 1 |
| Azabji-Kenfack, M | 1 |
| Dehayem, M | 1 |
| Onana, A | 1 |
| Biwole, D | 1 |
| Kaze, F | 1 |
| Gautier, JF | 1 |
| Mbanya, JC | 1 |
| Vogt, L | 1 |
| Chiurchiu, C | 1 |
| Chadha-Boreham, H | 2 |
| Danaietash, P | 1 |
| Hadjadj, S | 1 |
| Krum, H | 1 |
| Navis, G | 1 |
| Neuhart, E | 1 |
| Parvanova, AI | 1 |
| Ruggenenti, P | 1 |
| Woittiez, AJ | 1 |
| Zimlichman, R | 1 |
| Remuzzi, G | 1 |
| de Zeeuw, D | 1 |
| Maalouf, NM | 1 |
| Cameron, MA | 1 |
| Moe, OW | 1 |
| Sakhaee, K | 1 |
| Ekberg, NR | 1 |
| Brismar, K | 1 |
| Malmstedt, J | 1 |
| Hedblad, MA | 1 |
| Adamson, U | 1 |
| Ungerstedt, U | 1 |
| Wisniewski, N | 1 |
| Zhang, LN | 1 |
| Vincelette, J | 1 |
| Gless, RD | 1 |
| Anandan, SK | 1 |
| Rubanyi, GM | 1 |
| Webb, HK | 1 |
| MacIntyre, DE | 1 |
| Wang, YX | 1 |
| Gannon, MC | 1 |
| Nuttall, FQ | 1 |
| Xu, J | 1 |
| Wei, WB | 1 |
| Yuan, MX | 1 |
| Yuan, SY | 1 |
| Wan, G | 1 |
| Zheng, YY | 1 |
| Li, YB | 1 |
| Xu, L | 1 |
| Fu, HJ | 1 |
| Zhu, LX | 1 |
| Pu, XL | 1 |
| Zhang, JD | 1 |
| Du, XP | 1 |
| Li, YL | 1 |
| Ji, Y | 1 |
| Gu, XN | 1 |
| Pan, SF | 1 |
| Cui, XL | 1 |
| Bai, W | 1 |
| Chen, YJ | 1 |
| Wang, ZM | 1 |
| Zhu, QS | 1 |
| Liu, DY | 1 |
| Ji, YT | 1 |
| Yang, Z | 1 |
| Jonas, JB | 1 |
| Shahid, SM | 1 |
| Nawab, SN | 1 |
| Shaikh, R | 1 |
| Mahboob, T | 1 |
| Ning, M | 1 |
| Zou, Q | 1 |
| Leng, Y | 1 |
| Fleseriu, M | 1 |
| Biller, BM | 1 |
| Findling, JW | 1 |
| Molitch, ME | 1 |
| Schteingart, DE | 1 |
| Gross, C | 1 |
| Hussain, TA | 1 |
| Mathew, TC | 1 |
| Dashti, AA | 1 |
| Asfar, S | 1 |
| Al-Zaid, N | 1 |
| Dashti, HM | 1 |
| Guglielmino, K | 1 |
| Jackson, K | 1 |
| Vu, V | 1 |
| Dutrow, G | 1 |
| Evans, JE | 1 |
| Graham, J | 1 |
| Cummings, BP | 1 |
| Havel, PJ | 1 |
| Viswanathan, V | 1 |
| Tilak, P | 1 |
| Kumpatla, S | 1 |
| Salako, BL | 1 |
| Finomo, FO | 1 |
| Kadiri, S | 1 |
| Arije, A | 1 |
| Olatosin, AO | 1 |
| Meshcheriakova, VA | 1 |
| Plotnikova, OA | 1 |
| Sharafetdinov, KhKh | 1 |
| Iatsyshina, TA | 1 |
| Harmankaya, O | 1 |
| Seber, S | 1 |
| Yilmaz, M | 1 |
| Shakerhosseini, R | 1 |
| Atabak, S | 1 |
| Jamshidian, M | 1 |
| Mehrabi, Y | 1 |
| Esmaill-Zadeh, A | 1 |
| Geissler, A | 1 |
| Fründ, R | 1 |
| Schölmerich, J | 1 |
| Feuerbach, S | 1 |
| Zietz, B | 1 |
| Kim, NH | 1 |
| Kim, KB | 1 |
| Kim, DL | 1 |
| Kim, SG | 1 |
| Choi, KM | 1 |
| Baik, SH | 1 |
| Choi, DS | 1 |
| Kang, YS | 1 |
| Han, SY | 1 |
| Han, KH | 1 |
| Ji, YH | 1 |
| Cha, DR | 1 |
| Melano, E | 1 |
| Rodriguez, HL | 1 |
| Carrillo, R | 1 |
| Dillon, L | 1 |
| Kiran, M | 1 |
| Arpak, N | 1 |
| Unsal, E | 1 |
| Erdoğan, MF | 1 |
| Klabunde, T | 1 |
| Wendt, KU | 1 |
| Kadereit, D | 1 |
| Brachvogel, V | 1 |
| Burger, HJ | 1 |
| Herling, AW | 1 |
| Oikonomakos, NG | 1 |
| Kosmopoulou, MN | 1 |
| Schmoll, D | 1 |
| Sarubbi, E | 1 |
| von Roedern, E | 1 |
| Schönafinger, K | 1 |
| Defossa, E | 1 |
| Gadzama, AA | 1 |
| Mshelia, DS | 1 |
| Nyandaiti, Y | 1 |
| Wagner, FD | 1 |
| Bohnemeier, H | 1 |
| Jungnik, A | 1 |
| Halabi, A | 1 |
| Cyganek, K | 1 |
| Mirkiewicz-Sieradzka, B | 1 |
| Malecki, MT | 1 |
| Wolkow, P | 1 |
| Skupien, J | 1 |
| Bobrek, J | 1 |
| Czogala, M | 1 |
| Klupa, T | 1 |
| Sieradzki, J | 1 |
| Torres-Rodríguez, JM | 1 |
| Sellart-Altisent, M | 1 |
| Silove, M | 1 |
| Cameron-Clarke, A | 1 |
| Manchester, KL | 1 |
| Patel, JC | 2 |
| Sawant, MS | 2 |
| Almdal, TP | 1 |
| Jensen, T | 1 |
| Vilstrup, H | 1 |
| Silveiro, SP | 1 |
| Friedman, R | 1 |
| Gross, JL | 1 |
| Lin, JJ | 1 |
| Wadhwa, NK | 1 |
| Suh, H | 1 |
| Cabralda, T | 1 |
| Perfetto, F | 1 |
| Tarquini, R | 1 |
| de Leonardis, V | 1 |
| Piluso, A | 1 |
| Lombardi, V | 1 |
| Tarquini, B | 1 |
| Yoshioka, M | 1 |
| Kayo, T | 1 |
| Ikeda, T | 1 |
| Koizumi, A | 1 |
| Ragoobirsingh, D | 1 |
| Bennett, F | 1 |
| Morrison, EY | 1 |
| Nguyen, HT | 1 |
| Shannon, AG | 1 |
| Coates, PA | 1 |
| Owens, DR | 1 |
| Spira, A | 1 |
| Gowrishankar, M | 1 |
| Halperin, ML | 1 |
| Chattington, PD | 1 |
| Anderson, JV | 1 |
| Rees, LH | 1 |
| Leese, GP | 1 |
| Peters, JR | 1 |
| Vora, JP | 1 |
| Pijls, LT | 2 |
| de Vries, H | 2 |
| Donker, AJ | 2 |
| van Eijk, JT | 2 |
| Amyot, SL | 1 |
| Leblanc, M | 1 |
| Thibeault, Y | 1 |
| Geadah, D | 1 |
| Cardinal, J | 1 |
| Gougeon, R | 1 |
| Styhler, K | 1 |
| Morais, JA | 1 |
| Jones, PJ | 1 |
| Marliss, EB | 1 |
| Daniele, SM | 1 |
| Arriaga, S | 1 |
| Martínez, SM | 1 |
| Tarrés, MC | 1 |
| Montenegro, SM | 1 |
| D'Ottavio, AE | 1 |
| Hisano, N | 1 |
| Picena, JC | 1 |
| Morisoli, L | 1 |
| Haluzik, M | 1 |
| Sulková, S | 1 |
| Svobodová, J | 1 |
| Bedárová, V | 1 |
| Bodláková, B | 1 |
| Marková, M | 1 |
| Turková, G | 1 |
| Jiskra, J | 1 |
| Haas, T | 1 |
| Amin, BM | 1 |
| Marchesini, G | 1 |
| Zaccheroni, V | 1 |
| Brizi, M | 1 |
| Natale, S | 1 |
| Forlani, G | 1 |
| Bianchi, G | 1 |
| Baraldi, L | 1 |
| Melchionda, N | 1 |
| Doorenbos, CJ | 1 |
| Bosma, RJ | 1 |
| Lamberts, PJ | 1 |
| Weisshaar, E | 1 |
| Bonnekoh, B | 1 |
| Franke, I | 1 |
| Gollnick, H | 1 |
| Haynes, AC | 1 |
| Chapman, H | 1 |
| Taylor, C | 1 |
| Moore, GB | 1 |
| Cawthorne, MA | 1 |
| Tadayyon, M | 1 |
| Clapham, JC | 1 |
| Arch, JR | 1 |
| Wolever, TM | 1 |
| Jenkins, DJ | 1 |
| Vuksan, V | 1 |
| Jenkins, AL | 1 |
| Buckley, GC | 1 |
| Wong, GS | 1 |
| Josse, RG | 1 |
| Válek, J | 1 |
| Vlasáková, Z | 1 |
| Pelikánová, J | 1 |
| Karasová, I | 1 |
| Jirkovská, A | 1 |
| Grafnetter, D | 1 |
| Ishihara, M | 1 |
| Shinoda, T | 1 |
| Yamada, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health[NCT02931630] | 72 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| Functional Impact of GLP-1 for Heart Failure Treatment[NCT01800968] | Phase 2 | 300 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| 2895 Effect of a High Protein Diet on the 24-hr Profile of Ghrelin, GH and IGF-1[NCT00108225] | 8 participants (Actual) | Interventional | 2004-07-31 | Completed | |||
| An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome[NCT00569582] | Phase 3 | 50 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Mifepristone Treatment for Breast Cancer Patients Expressing Levels of Progesterone Receptor Isoform A (PRA) Higher Than Those of Isoform B (PRB): Neoadjuvant Therapy.[NCT02651844] | 20 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine[NCT02160730] | Phase 2 | 4 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to NIH grant ended.) | ||
| Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309] | 465 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma[NCT05119010] | 60 participants (Anticipated) | Interventional | 2023-03-24 | Recruiting | |||
| Impact of Combined Non-surgical and Surgical Periodontal Treatment in Patients With Type 2 Diabetes Mellitus[NCT02874963] | 160 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in 6 minute walk distance baseline to 180 days. (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | meters (Mean) |
|---|---|
| Liraglutide | 55.7 |
| Placebo | 55.3 |
Change in 6 minute walk distance baseline to 90 days. (NCT01800968)
Timeframe: Baseline to 90 days
| Intervention | meters (Mean) |
|---|---|
| Liraglutide | 56.8 |
| Placebo | 38.7 |
Change in 6 minute walk distance baseline to day 30 (NCT01800968)
Timeframe: Baseline to day 30
| Intervention | meters (Mean) |
|---|---|
| Liraglutide | 50.4 |
| Placebo | 37.3 |
Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 30 days. The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01800968)
Timeframe: Baseline to 30 days
| Intervention | units on a scale (Mean) |
|---|---|
| Liraglutide | 14.69 |
| Placebo | 14.44 |
Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01800968)
Timeframe: Baseline to 90 days
| Intervention | units on a scale (Mean) |
|---|---|
| Liraglutide | 13.86 |
| Placebo | 11.72 |
Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to day 180.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01800968)
Timeframe: Baseline to day 180
| Intervention | units on a scale (Mean) |
|---|---|
| Liraglutide | 13.79 |
| Placebo | 13.14 |
Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 30 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01800968)
Timeframe: Baseline to 30 days
| Intervention | units on a scale (Mean) |
|---|---|
| Liraglutide | 12.98 |
| Placebo | 14.01 |
Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01800968)
Timeframe: Baseline to 90 days
| Intervention | units on a scale (Mean) |
|---|---|
| Liraglutide | 14.17 |
| Placebo | 10.62 |
Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 180 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | units on a scale (Mean) |
|---|---|
| Liraglutide | 13.44 |
| Placebo | 13.25 |
Change in lateral filling pressure baseline to day 180. (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | m/sec (Mean) |
|---|---|
| Liraglutide | -0.05 |
| Placebo | 0.39 |
Change in left ventricular ejection fraction from baseline to day 180 (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | percent (Mean) |
|---|---|
| Liraglutide | 1.07 |
| Placebo | 1.37 |
Change in Left Ventricular End-Diastolic Volume Index from baseline to 180 days. (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | ml per meter squared (Mean) |
|---|---|
| Liraglutide | 3.37 |
| Placebo | -2.91 |
Change in left ventricular end-systolic volume index from baseline to day 180. (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | ml per meter squared (Mean) |
|---|---|
| Liraglutide | 1.16 |
| Placebo | -3.47 |
Change in medial filling pressure baseline to day 180. (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | m/sec (Mean) |
|---|---|
| Liraglutide | 1.12 |
| Placebo | 0.25 |
A rank score based on time to death, time to adjudicated heart failure hospitalization, and time-averaged proportional change in NTproBNP through d180. For patients that died, the patient with the shortest time from randomization to death is assigned rank 1, the second shortest time is assigned rank 2, etc. The patient with the longest time from randomization to death is assigned rank X. For patients that did not die but had a heart failure hospitalization, the patient with the shortest time from randomization to re-admission is assigned rank X+1 and the patient with the longest time from randomization to heart failure hospitalization is assigned rank Y. For patients that did not die or have a heart failure hospitalization, increases in time-averaged proportional change in NTproBNP indicate a worse result and the largest increase is assigned rank Y+1. The patient with the largest decrease is assigned rank N, where N is the sample size. (NCT01800968)
Timeframe: Randomization to 180 days
| Intervention | rank (Mean) |
|---|---|
| Liraglutide | 145.5 |
| Placebo | 155.7 |
A rank score based on time to death, time to adjudicated heart failure hospitalization, time to emergency department visit and time-averaged proportional change in NTproBNP through d180. See Outcome Measure 1 for a general description of the outcome derivation. (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | rank (Mean) |
|---|---|
| Liraglutide | 144.29 |
| Placebo | 157.05 |
Individual component of the primary endpoint- Heart Failure hospitalization from randomization to 180 days (NCT01800968)
Timeframe: Randomization to 180 days
| Intervention | participants (Number) |
|---|---|
| Liraglutide | 63 |
| Placebo | 50 |
Individual component of the primary endpoint of mortality at 180 days after randomization (NCT01800968)
Timeframe: Randomization to 180 days
| Intervention | participants (Number) |
|---|---|
| Liraglutide | 19 |
| Placebo | 16 |
Individual component of the primary endpoint- time-averaged proportional change in NT-proBNP from baseline to 180 days (NCT01800968)
Timeframe: Baseline to 180 days
| Intervention | weighted average of ratio to baseline (Mean) |
|---|---|
| Liraglutide | 335.81 |
| Placebo | 317 |
Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit. (NCT00569582)
Timeframe: Baseline to Week 24
| Intervention | participants (Number) |
|---|---|
| Mifepristone | 8 |
Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance. (NCT00569582)
Timeframe: Baseline to Week 24
| Intervention | participants (Number) |
|---|---|
| Mifepristone | 15 |
The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4. (NCT02160730)
Timeframe: Baseline, Week 4
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
"To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. Normalizing is defined as having urine free cortisol levels within the normal range for that lab value." (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | lbs (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 217 | 217.4 |
Mean diastolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 76.5 | 71 |
HbA1c levels are measured at baseline and at study end, these are averaged across all subjects. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | Percentage (Mean) | |
|---|---|---|
| Baseline | Study End-4 weeks | |
| R-roscovitine | 6.9 | 7 |
Mean change in systolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 150.3 | 128.3 |
Mean serum cortisol values at baseline and 4 weeks (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 25.6 | 27.1 |
Mean change between baseline and week 4 of fasting blood glucose levels. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | g/dL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 121.4 | 104.3 |
Mean change in Plasma ACTH between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 79.3 | 79.9 |
3 reviews available for urea and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review.
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Sodium; Ure | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.
Topics: Benzazepines; Diabetes Mellitus, Type 2; Heart Valve Diseases; Humans; Molecular Structure; Obesity; | 2013 |
27 trials available for urea and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The Effects of 12-Weeks Whey Protein Supplements on Markers of Bone Turnover in Adults With Abdominal Obesity - A
Topics: Adult; Biomarkers; Bone Remodeling; Calcium; Diabetes Mellitus, Type 2; Dietary Fiber; Humans; Insul | 2022 |
Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Heart Failure; Humans; Liraglutide; Stroke Volume; Urea | 2022 |
The effect of a 6-month walking program on biochemical parameters in sedentary adults with type 2 diabetes mellitus.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; C-Reactive Prot | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Topics: Adenosine; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Blood Glucose; Cardiac | 2017 |
Use of a urea, arginine and carnosine cream versus a standard emollient glycerol cream for treatment of severe xerosis of the feet in patients with type 2 diabetes: a randomized, 8 month, assessor-blinded, controlled trial.
Topics: Administration, Cutaneous; Aged; Arginine; Carnosine; Diabetes Mellitus, Type 2; Emollients; Female; | 2015 |
Clinical evaluation of plasma insulin and C-peptide levels with 3 different high-flux dialyzers in diabetic patients on hemodialysis.
Topics: Blood Glucose; C-Peptide; Cellulose; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 2; Diab | 2008 |
Soy-protein consumption and kidney-related biomarkers among type 2 diabetics: a crossover, randomized clinical trial.
Topics: Aged; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet; Dieta | 2009 |
Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Te | 2009 |
Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis.
Topics: Blood Glucose; Blood Urea Nitrogen; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relat | 2010 |
Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Cross-Over Studies; D | 2010 |
Metabolic basis for low urine pH in type 2 diabetes.
Topics: Adult; Age Factors; Aged; Biomarkers; Body Mass Index; Buffers; Diabetes Mellitus, Type 2; Diabetic | 2010 |
Effect of a high-protein diet on ghrelin, growth hormone, and insulin-like growth factor-I and binding proteins 1 and 3 in subjects with type 2 diabetes mellitus.
Topics: Aged; Body Weight; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Proteins; Ghre | 2011 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushin | 2012 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
An urea, arginine and carnosine based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the treatment of severe xerosis of the feet in Type 2 diabetic patients in comparison with glycerol-based emollient cream. A randomized, assessor-blinded, controll
Topics: Administration, Topical; Adult; Aged; Arginine; Carnosine; Diabetes Mellitus, Type 2; Diabetic Foot; | 2012 |
Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 2002 |
[The use of the combined food products with soy protein in diet therapy for patients with diabetes mellitus type 2].
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Body Weight; Cholesterol; Creatinine; Diab | 2002 |
Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.
Topics: Aged; Albumins; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; C | 2003 |
Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy.
Topics: Cardiovascular Diseases; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephro | 2003 |
The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dental Plaque Index; De | 2005 |
Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2006 |
Control of non-insulin-dependent diabetes mellitus partially normalizes the increase in hepatic efficacy for urea synthesis.
Topics: Adult; Aged; Alanine; Body Water; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobi | 1994 |
Atrial natriuretic peptide in type 2 diabetes mellitus: response to a physiological mixed meal and relationship to renal function.
Topics: Adult; Aged; Analysis of Variance; Atrial Natriuretic Factor; Blood Glucose; Blood Pressure; Diabete | 1998 |
Adherence to protein restriction in patients with type 2 diabetes mellitus: a randomized trial.
Topics: Aged; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dietary Proteins; Female; Humans; Line | 2000 |
Levels of lactic acid, normal level & its relation to food, glucose, cholesterol, raised blood urea and phenformin therapy.
Topics: Diabetes Mellitus, Type 2; Diet; Female; Humans; Hypercholesterolemia; Hyperglycemia; India; Lactic | 2000 |
Systemic prostaglandin E1 infusion and hepatic aminonitrogen to urea nitrogen conversion in patients with type 2 diabetes in poor metabolic control.
Topics: Aged; Alanine; Alprostadil; Anthropometry; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Human | 2001 |
83 other studies available for urea and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Urinary IgG, serum CX3CL1 and miRNA-152-3p: as predictors of nephropathy in Egyptian type 2 diabetic patients.
Topics: Albumins; Chemokine CX3CL1; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic | 2022 |
Discovery of DS68702229 as a Potent, Orally Available NAMPT (Nicotinamide Phosphoribosyltransferase) Activator.
Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Humans; Male; Mice, Obese; NAD | 2021 |
Clinical profiling and screening for HNF4α and GCK gene mutations in Kashmiri patients with maturity-onset diabetes of the young (MODY).
Topics: Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucokinase; Glycated He | 2022 |
In silico studies of the human IAPP in the presence of osmolytes.
Topics: Amyloid; Diabetes Mellitus, Type 2; Humans; Islet Amyloid Polypeptide; Protein Structure, Secondary; | 2022 |
Age, Pulse, Urea, and Albumin Score: A Tool for Predicting the Short-Term and Long-Term Outcomes of Community-Acquired Pneumonia Patients With Diabetes.
Topics: Albumins; Community-Acquired Infections; Diabetes Mellitus, Type 2; Humans; Pneumonia; Retrospective | 2022 |
LPD significantly reduces urinary urea and HbA1c in diabetic nephropathy?
Topics: Albuminuria; Blood Urea Nitrogen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemogl | 2022 |
Prevalence and risk factors of diabetic retinopathy among Chinese adults with type 2 diabetes in a suburb of Shanghai, China.
Topics: Adult; Aged; Albumins; Blood Glucose; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dia | 2022 |
Ultrasonography Combined with Blood Biochemistry on the Early Diagnosis of Diabetic Kidney Disease.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early Diagnosis; Humans; Kidney; Ultr | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study.
Topics: Adult; Blood Urea Nitrogen; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Humans; | 2022 |
The association between time in the glucose target range and abnormal ankle-brachial index: a cross-sectional analysis.
Topics: Ankle Brachial Index; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Sectional Studies; Diabete | 2022 |
The association between time in the glucose target range and abnormal ankle-brachial index: a cross-sectional analysis.
Topics: Ankle Brachial Index; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Sectional Studies; Diabete | 2022 |
The association between time in the glucose target range and abnormal ankle-brachial index: a cross-sectional analysis.
Topics: Ankle Brachial Index; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Sectional Studies; Diabete | 2022 |
The association between time in the glucose target range and abnormal ankle-brachial index: a cross-sectional analysis.
Topics: Ankle Brachial Index; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Sectional Studies; Diabete | 2022 |
Use of Saliva to Assess the Adherence to Treatment with Oral Hypoglycemic Agents in Patients with Type 2 Diabetes.
Topics: Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemi | 2023 |
Effects of Dietary Sodium and Protein Intake on Glomerular Filtration Rate in Subjects with Type 2 Diabetes Treated with Sodium-Glucose Cotransporter 2 Inhibitors.
Topics: Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucose; Humans; Sodium; Sodium Chloride, Die | 2023 |
Associations of serum amino acids related to urea cycle with risk of chronic kidney disease in Chinese with type 2 diabetes.
Topics: Arginine; Citrulline; Diabetes Mellitus, Type 2; East Asian People; Female; Humans; Male; Ornithine; | 2023 |
Association between serum urea concentrations and the risk of colorectal cancer, particularly in individuals with type 2 diabetes: A cohort study.
Topics: Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Risk Factors; Urea | 2024 |
Diabetes mellitus drug discovery: insights into targeting feline and human amylin with small molecules.
Topics: Amyloid; Animals; Cat Diseases; Cats; Diabetes Mellitus, Type 2; Humans; Islet Amyloid Polypeptide; | 2023 |
Altered red blood cell deformability-A novel hypothesis for retinal microangiopathy in diabetic retinopathy.
Topics: Adult; Aged; Biomarkers; Biomechanical Phenomena; Case-Control Studies; Cross-Sectional Studies; Dia | 2020 |
Oxidative stress as a potential mechanism by which guanylurea disrupts the embryogenesis of Danio rerio.
Topics: Animals; Diabetes Mellitus, Type 2; Embryo, Nonmammalian; Embryonic Development; Guanidine; Oxidativ | 2021 |
Quantification of sweat urea in diabetes using electro-optical technique.
Topics: Diabetes Mellitus, Type 2; Humans; Sweat; Urea; Water | 2021 |
Kyrle's disease: a cutaneous manifestation of diabetes mellitus.
Topics: Antipruritics; Biopsy; Darier Disease; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; H | 2017 |
Influence of C-reactive protein on the occurrence and assessing of albuminuria severity in diabetics.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Biomarkers; Blood Glucose; C-Reactive Protein; Creatini | 2018 |
Protective Effect of
Topics: Animals; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2018 |
Effect of microalbuminuria on macular thickness in patients with type-2 diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fovea | 2020 |
Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1.
Topics: Bile; Bile Acids and Salts; Diabetes Mellitus, Type 2; HEK293 Cells; Humans; Ligands; Non-alcoholic | 2019 |
Salivary Profile in Adult Type 2 Diabetes Mellitus Patients: A Case-control Study.
Topics: Adult; Blood Glucose; Calcium; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glycated Hem | 2019 |
Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.
Topics: Administration, Cutaneous; Animals; Benzoates; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabe | 2019 |
Severe hypernatremia from a urea-induced diuresis due to body protein wasting in an insulin-resistant type 2 diabetic patient.
Topics: Diabetes Mellitus, Type 2; Diuresis; Electrolytes; Glucocorticoids; Humans; Hypernatremia; Hypertens | 2013 |
Cosolvent effects on the fibrillation reaction of human IAPP.
Topics: Amyloid; Betaine; Diabetes Mellitus, Type 2; Humans; Islet Amyloid Polypeptide; Methylamines; Protei | 2013 |
Influence of coffee brew in metabolic syndrome and type 2 diabetes.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Cholesterol, | 2013 |
Increased erythrocytes by-products of arginine catabolism are associated with hyperglycemia and could be involved in the pathogenesis of type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Blood Glucose; Carbon Isotopes; Case-Control Studies; Citrulline; Diabetes Me | 2013 |
Hyperglycaemia during exacerbations of asthma and chronic obstructive pulmonary disease.
Topics: Acute Disease; Aged; Aged, 80 and over; Asthma; Blood Glucose; C-Reactive Protein; Comorbidity; Diab | 2013 |
The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Genotype; Glycated Hemogl | 2014 |
Perifornical hypothalamic orexin and serotonin modulate the counterregulatory response to hypoglycemic and glucoprivic stimuli.
Topics: Animals; Astrocytes; Benzoxazoles; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 1; Diabet | 2015 |
Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model.
Topics: Adamantane; Animals; Animals, Genetically Modified; Calcium; Cardiomegaly; Diabetes Mellitus, Type 2 | 2014 |
Serum haematological and biochemical indices of oxidative stress and their relationship with DNA damage and homocysteine in Pakistani type II diabetic patients.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Case-Cont | 2015 |
Glycogen phosphorylase as a target for type 2 diabetes: synthetic, biochemical, structural and computational evaluation of novel N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors.
Topics: Animals; Binding, Competitive; Computational Biology; Crystallography, X-Ray; Diabetes Mellitus, Typ | 2015 |
Helicobacter pylori infection is associated with type 2 diabetes among a middle- and old-age Chinese population.
Topics: Age Factors; Aged; Breath Tests; Carbon Radioisotopes; China; Cohort Studies; Cross-Sectional Studie | 2016 |
Monitoring Diabetic Nephropathy by Circulating Gangliosides.
Topics: Aged; Albuminuria; Biomarkers; Blood Glucose; Case-Control Studies; Creatinine; Diabetes Mellitus, T | 2016 |
Discovery of ethyl urea derivatives as inhibitors of islet amyloid polypeptide fibrillization and cytotoxicity.
Topics: Amyloid; Amyloidosis; Diabetes Mellitus, Type 2; Humans; Islet Amyloid Polypeptide; Islets of Langer | 2016 |
Salivary profile in diabetic patients: biochemical and immunological evaluation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amylases; Antibodies, Bacterial; Calcium; Case-Control S | 2016 |
A case-control study of prevalence of anemia among patients with type 2 diabetes.
Topics: Adult; Aged; Anemia; Blood Glucose; Calcium; Case-Control Studies; Creatinine; Diabetes Mellitus, Ty | 2016 |
Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes.
Topics: 3T3 Cells; Albumins; Animals; Blood Glucose; Cell Line; Coculture Techniques; Cytochrome P-450 CYP1A | 2016 |
The Metabolic Responses to L-Glutamine of Livers from Rats with Diabetes Types 1 and 2.
Topics: Alanine; Ammonia; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gluconeogenesis; Gl | 2016 |
Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS.
Topics: Amino Acids, Branched-Chain; Asian People; Blood Glucose; Case-Control Studies; Chromatography, Liqu | 2016 |
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Topics: Adamantane; Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2016 |
Diabetes: Urea inhibits insulin secretion in CKD.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Insulin; Renal Insufficiency, Chronic; Urea | 2016 |
INCREASED SERUM LEVELS OF UREA AND CREATININE ARE SURROGATE MARKERS FOR DISRUPTION OF RETINAL PHOTORECEPTOR EXTERNAL LIMITING MEMBRANE AND INNER SEGMENT ELLIPSOID ZONE IN TYPE 2 DIABETES MELLITUS.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Case-Control Studies; Creatinine; Diabetes Mellitus, | 2017 |
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
Topics: Animals; Blood Glucose; Combinatorial Chemistry Techniques; Crystallography, X-Ray; Diabetes Mellitu | 2009 |
Early renal failure detection by cystatin C in Type 2 diabetes mellitus: varying patterns of renal analyte expression.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Biomarkers; Blood Glucose; Cholesterol, LDL; Creatinine | 2009 |
Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Glucok | 2009 |
Analyte flux at a biomaterial-tissue interface over time: implications for sensors for type 1 and 2 diabetes mellitus.
Topics: Adult; Aged; Biocompatible Materials; Biopsy; Biosensing Techniques; Diabetes Mellitus, Type 1; Diab | 2010 |
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Topics: Adamantane; Administration, Oral; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2011 |
Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Mass Index; China; Community Hea | 2012 |
Glycemic control, dyslipidemia and endothelial dysfunction in coexisted diabetes, hypertension and nephropathy.
Topics: Albuminuria; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 2012 |
Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Diabetes Mellitus, Type 2; Enzyme Activation; | 2012 |
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
Topics: Adamantane; Animals; Blood Glucose; Blotting, Western; Calcium Signaling; Crosses, Genetic; Diabetes | 2012 |
Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: a 12 years observational study.
Topics: Age Factors; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glyca | 2012 |
Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy.
Topics: Adult; Aspartic Acid; Blood Glucose; Brain; Chlorides; Choline; Creatinine; Diabetes Mellitus, Type | 2003 |
Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
Topics: Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Fe | 2004 |
The effects of Panafil when using topical negative pressure to heal an infected sternal wound.
Topics: Administration, Cutaneous; Anti-Infective Agents; Chlorophyllides; Combined Modality Therapy; Corona | 2004 |
Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
Topics: Adenosine Monophosphate; Allosteric Site; Animals; Binding Sites; Crystallography, X-Ray; Diabetes M | 2005 |
Pattern of biochemistry laboratory requests and results in north eastern Nigeria.
Topics: Blood Glucose; Calcium; Clinical Laboratory Techniques; Creatinine; Developing Countries; Diabetes M | 2006 |
Clinical risk factors and the role of VDR gene polymorphisms in diabetic retinopathy in Polish type 2 diabetes patients.
Topics: Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Di | 2006 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug R | 2006 |
Protein and fat metabolism of hepatocytes from hyperosmolar non-ketotic diabetic rats.
Topics: Animals; Diabetes Mellitus, Type 2; Hydroxybutyrates; Liver; Osmolar Concentration; Proteins; Rats; | 1984 |
Levels of lactic acid in normal Indians & its relation to food, glucose, cholesterol, raised blood urea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Child; Cholesterol; Diabetes Mellitus, Ty | 1993 |
Glomerular hyperfiltration in NIDDM patients without overt proteinuria.
Topics: Blood Glucose; Blood Pressure; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fema | 1993 |
Peritoneal transport in type I (insulin-dependent) and type II (noninsulin-dependent) diabetic peritoneal dialysis patients.
Topics: Adult; Biological Transport; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabe | 1995 |
Angiopathy affects circulating endothelin-1 levels in type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Creatine; Diabetes Mellitus | 1995 |
A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Chromosomes, Human, Pair | 1997 |
Kidney function in phasic insulin dependent diabetes mellitus in Jamaica.
Topics: Albuminuria; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 1997 |
Estimation of glomerular filtration rate in type II (non-insulin dependent) diabetes mellitus patients.
Topics: Adult; Age Factors; Aged; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Edetic Acid; Female | 1997 |
Factors contributing to the degree of polyuria in a patient with poorly controlled diabetes mellitus.
Topics: Absorption; Aged; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diuresis; Glucose; Glycosuria; | 1997 |
Reproducibility and biomarker-based validity and responsiveness of a food frequency questionnaire to estimate protein intake.
Topics: Aged; Bias; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diet Surveys; Diet, Diabetic; Di | 1999 |
Myoglobin clearance and removal during continuous venovenous hemofiltration.
Topics: Acrylic Resins; Acute Kidney Injury; Adult; Creatinine; Dehydration; Diabetes Mellitus, Type 2; Hemo | 1999 |
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati | 2000 |
Onset and evolution of nephropathy in rats with spontaneous diabetes mellitus.
Topics: Animals; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2000 |
Serum leptin levels in diabetic patients on hemodialysis: the relationship to parameters of diabetes metabolic control.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female | 2000 |
Use of urea containing dialysate to avoid disequilibrium syndrome, enabling intensive dialysis treatment of a diabetic patient with renal failure and severe metformin induced lactic acidosis.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglyce | 2001 |
[Successful symptomatic tazarotene treatment of juvenile acanthosis nigricans of the familial obesity-associated type in insulin resistance].
Topics: Acanthosis Nigricans; Administration, Topical; Child; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 2001 |
Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice.
Topics: Adipose Tissue, Brown; Animals; Benzoxazoles; Body Composition; Body Weight; Diabetes Mellitus, Type | 2002 |
Beneficial effect of a low glycaemic index diet in type 2 diabetes.
Topics: Aged; Biomarkers; Blood Glucose; C-Peptide; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Diet | 1992 |
[The effect of elevated blood glucose levels and body weight on the metabolic profile in type 2 diabetes after long-term therapy].
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Electrolytes; Female; Humans; Lipi | 1990 |
Co-occurrence of hypercalciuria and hypouricaemia in type 2 diabetic patients.
Topics: Blood Pressure; Calcium; Creatinine; Diabetes Mellitus, Type 2; Humans; Middle Aged; Phosphates; Ref | 1989 |